Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19250795 | COMPOSITION | June 2025 | February 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19230710 | Animal Feeds and Feed Premixes Containing Betaine and a Phytase | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19030861 | TREATMENT OF IMMUNE DISORDERS | January 2025 | January 2026 | Allow | 12 | 1 | 0 | No | No |
| 19022162 | PROTEOLYTIC ENZYME COMPOSITION | January 2025 | September 2025 | Allow | 8 | 2 | 0 | No | No |
| 18653104 | Agricultural compositions and methods for the delivery of plant health-promoting microbes | May 2024 | March 2026 | Allow | 22 | 3 | 1 | Yes | No |
| 18631626 | POPULATION GENETICS APPROACH TO BIOLOGICAL CONTROL OF MYCOTOXIN PRODUCTION | April 2024 | August 2025 | Allow | 16 | 1 | 1 | No | No |
| 18625676 | Animal Feeds and Feed Premixes Containing Betaine Hydrochloride and a Phytase | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18606927 | CLINICAL FORMULATIONS | March 2024 | May 2025 | Allow | 14 | 2 | 0 | No | No |
| 18589142 | Methods and Compositions Relating to Microbial Treatment and Diagnosis of Disorders | February 2024 | September 2025 | Allow | 19 | 2 | 0 | No | No |
| 18545335 | CELL CULTURE MEDIA COMPOSITIONS FOR PRIMARY CELLS | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18524351 | MICROBIAL COMPOSITIONS AND METHODS FOR RUMINANT HEALTH AND PERFORMANCE | November 2023 | October 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18516940 | GRANULE FOR DETECTING GLUCOSE IN PET URINE AND METHOD FOR PREPARING THE SAME | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18506179 | POLYPEPTIDES HAVING LYZOZYME ACTIVITY, POLUNUCLEOTIDES ENCODING SAME AND USES AND COMPOSITIONS THEREOF | November 2023 | June 2025 | Allow | 19 | 1 | 1 | No | No |
| 18464583 | TREATMENT OF STRESS DISORDERS USING ACETYLCHOLINE RELEASE INHIBITING NEUROTOXIC PROTEINS TO REDUCE STRESS LEVELS | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18241009 | Bifidobacterium longum subsp. infantis with fimbriae and applications thereof | August 2023 | June 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18279040 | PROBIOTIC COMPOSITIONS USEFUL IN THE PREVENTION AND/OR TREATMENT OF GASTROINTESTINAL DISORDERS | August 2023 | March 2026 | Allow | 30 | 1 | 0 | No | No |
| 18446057 | METHOD FOR INCREASING FERROUS ION CONTENT IN BACILLUS COAGULANS AND COMPOUND MICROBIAL AGENT | August 2023 | August 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18446301 | ASPARTIC PROTEASE FOR TREATMENT OF GLUTEN INTOLEREANCE, NUCLEIC ACID MOLECULES ENCODING THE ASPARTIC PROTEASE, METHOD OF PRODUCING THE ASPARTIC PROTEASE, AND APPLICATION THEREOF | August 2023 | March 2026 | Allow | 31 | 0 | 1 | No | No |
| 18364080 | PRODUCING METHOD OF STRESS RELIEVER | August 2023 | December 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18357299 | TRANSGLUTAMINASE TREATED PRODUCTS | July 2023 | October 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18224418 | Methods for Lysis of Cells Within a Sample | July 2023 | February 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18215475 | Method for Inducing Lateral Branch Development of Eucheuma Denticulatum | June 2023 | July 2024 | Abandon | 13 | 2 | 0 | No | No |
| 18335889 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18267478 | BIOCONVERSION OF FERULIC ACID TO VANILLIN | June 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18267252 | COMPOSITION FOR TREATING OR PREVENTING MYOPATHY, OBESITY OR DIABETES | June 2023 | March 2026 | Allow | 33 | 1 | 1 | No | No |
| 18038143 | USE OF POLYPEPTIDE HAVING SUPEROXIDE DISMUTASE ACTIVITY AND EXTRACELLULAR VESICLES FOR TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTION | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18036805 | Process for the production of a technical enzyme composition with low viscosity produced by a filamentous fungus | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18143529 | GENERATION OF METHANE FROM DIGESTION OF MARINE BROWN ALGAE | May 2023 | October 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18142802 | DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE | May 2023 | March 2025 | Allow | 22 | 2 | 0 | No | No |
| 18029582 | Bacterial Superoxide Dismutases | March 2023 | May 2025 | Allow | 26 | 0 | 1 | No | No |
| 18028860 | A PROCESS TO TREAT A CARBON DIOXIDE COMPRISING GAS | March 2023 | January 2026 | Allow | 34 | 1 | 1 | No | No |
| 18186257 | METHODS FOR FERMENTATIVE PRODUCTION OF MASSOIA LACTONE | March 2023 | June 2024 | Allow | 15 | 0 | 0 | No | No |
| 18181944 | BATCH FEED PROCESS FOR FERMENTING SUGARS | March 2023 | December 2025 | Abandon | 33 | 2 | 0 | No | No |
| 18175330 | YOGURT FOR REGULATING INTESTINAL TRACT, PREPARATION METHOD THEREFOR, AND USE THEREOF | February 2023 | January 2026 | Allow | 35 | 2 | 0 | No | No |
| 18042793 | COMPOSITION COMPRISING TTF-NGR FOR USE IN TREATING SOFT-TISSUE SARCOMA | February 2023 | September 2025 | Allow | 31 | 1 | 0 | No | No |
| 18159664 | MANNOSYLERYTHRITOL LIPID BIOLOGICAL PESTICIDES AND APPLICATIONS THEREOF | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18016692 | COMPOSITION FOR PREVENTION OF DUMPING SYNDROME IN A POST-BARIATRIC SURGERY SETTING | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18146212 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | December 2022 | August 2024 | Allow | 20 | 1 | 0 | No | No |
| 18012069 | Use of Microorganisms to Improve Plant Immune Response | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18009243 | COMPOSITION FOR TREATMENT OF GLUTARIC ACIDURIA AND ADMINISTRATION METHOD THEREFOR | December 2022 | November 2025 | Abandon | 36 | 0 | 1 | No | No |
| 18071857 | COMPOSITIONS AND METHODS FOR TREATING PANCREATIC ENZYME DEFICIENCIES IN MAMMALS | November 2022 | July 2025 | Allow | 31 | 2 | 1 | No | No |
| 17999980 | NEW LIPASE ENZYME | November 2022 | October 2025 | Allow | 34 | 1 | 1 | No | No |
| 17999485 | ADAMTS13 COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING COMPLICATIONS OF CORONAVIRUS DISEASE | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 18056033 | DETECTION AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17924668 | ANTIVIRAL AGENT | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17984485 | MICROBIAL INOCULANT COMPOSITIONS AND METHODS | November 2022 | January 2026 | Allow | 39 | 2 | 1 | No | No |
| 17972941 | TREATEMENT OF PATHOGEN INFECTIONS FORMULATIONS AND METHODS FOR USE | October 2022 | October 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17996831 | PLASMINOGEN FOR USE IN TREATING AND PREVENTING LUNG DYSFUNCTION | October 2022 | August 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17938562 | COLD PROTEASE TREATMENT METHOD FOR PREPARING BIOLOGICAL SAMPLES | October 2022 | November 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17938487 | SYSTEMS AND METHODS FOR 4D PRINTING FOR MEMBRANOUS TISSUE FABRICATION | October 2022 | February 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17937759 | BIOCONTROL AGENTS FOR USE AGAINST SOIL AND AIR-BORNE FUNGAL PATHOGENS | October 2022 | September 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17955437 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | September 2022 | August 2025 | Allow | 35 | 1 | 1 | No | No |
| 17914265 | METHOD AND DRUG FOR TREATING ALZHEIMER DISEASE | September 2022 | January 2026 | Abandon | 40 | 1 | 1 | No | No |
| 17900130 | POMEGRANATE MOLASSES MEDIUM FOR CULTURING MICROBES | August 2022 | September 2023 | Allow | 12 | 2 | 1 | No | No |
| 17802280 | METHOD AND DRUG FOR PREVENTING AND TREATING ABNORMAL BLOOD PRESSURE CONDITION | August 2022 | January 2026 | Abandon | 41 | 1 | 1 | Yes | No |
| 17875473 | Methods and Reagents Useful for Verification of the Integrity of a Urine Sample and the Detection of Counterfeit Urine | July 2022 | July 2023 | Abandon | 12 | 1 | 1 | No | No |
| 17870936 | TREATMENT OF IMMUNE DISORDERS | July 2022 | November 2024 | Allow | 28 | 2 | 0 | No | No |
| 17847653 | MEDIUM SUPPLEMENT FOR HIGH-YIELD INDUSTRIAL CULTURE OF FASTIDIOUS ANAEROBES AND MEDIUM COMPOSITION CONTAINING THE SAME | June 2022 | February 2025 | Allow | 32 | 1 | 0 | No | No |
| 17847753 | FIBRINOLYTIC ENZYME COMPOSITION FOR FIBROSIS TREATMENT | June 2022 | July 2025 | Abandon | 37 | 3 | 1 | Yes | No |
| 17844858 | METHODS FOR PROPAGATING MICROORGANISMS FOR FERMENTATION & RELATED METHODS & SYSTEMS | June 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17787189 | EXTRACELLULAR VESICLES FROM MICROALGAE | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17767702 | COMPOSITION COMPRISING GRAIN-DERIVED LACTIC ACID BACTERIA FOR RELIEVING HANGOVER AND BOWEL TROUBLE | June 2022 | August 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17780633 | Method for Improving Olfactory Sensitivity | May 2022 | October 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17780358 | COMPOSITIONS AND METHODS FOR PRESERVING PROBIOTIC VIABILITY | May 2022 | August 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17748096 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | May 2022 | June 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17748304 | Pichia kudriavzevii and multifunctional complex microbial inoculant and use thereof | May 2022 | March 2025 | Allow | 34 | 1 | 1 | No | No |
| 17625864 | COMPOSITION CONTAINING PROPIONIBACTERIUM FREUDENREICHII AND USES THEREOF | May 2022 | April 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17776010 | METHOD FOR DETERMINING WHETHER OR NOT A SUBJECT HAS A PARKINSONIAN CONDITION | May 2022 | May 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17741865 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | May 2022 | July 2024 | Allow | 27 | 1 | 0 | No | No |
| 17772658 | METHOD OF FIXATING AND STABILIZING NITRIC OXIDE METABOLITES THROUGH FERMENTATION OF NITROGEN-CONTAINING NATURAL SUBSTANCE | April 2022 | March 2026 | Allow | 46 | 3 | 1 | No | No |
| 17754431 | NOVEL SKIN CARE COMPOSITION | April 2022 | October 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17765644 | IMPROVED ISOLATION OF STEVIOL GLYCOSIDES | March 2022 | February 2026 | Allow | 47 | 2 | 1 | No | No |
| 17709403 | SHORT IN VIVO HALF-LIFE AND IN VIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF | March 2022 | February 2024 | Allow | 23 | 3 | 1 | Yes | No |
| 17592623 | COMPOSITIONS AND METHODS FOR DETOXIFYING BACTERIAL ENDOTOXINS | February 2022 | October 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17577208 | FAECALIBACTERIUM PRAUSNITZII AND DESULFOVIBRIO PIGER FOR USE IN THE TREATMENT OR PREVENTION OF DIABETES AND BOWEL DISEASES | January 2022 | February 2025 | Allow | 37 | 2 | 0 | No | No |
| 17551942 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME | December 2021 | October 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17618705 | COMPOSITIONS AND METHODS FOR GROWING THE POPULATION OF MICROORGANISMS IN A GUT OF MONOGASTRIC ANIMALS | December 2021 | March 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17544717 | STREPTOMYCES ANTIOXIDANS AND ITS USE IN PREVENTION AND TREATMENT OF PLANT DISEASES | December 2021 | April 2023 | Allow | 17 | 2 | 0 | No | No |
| 17521501 | Microbial Diagnostic Sampling Swab | November 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17516875 | Corn Rootworm Biological Control | November 2021 | March 2024 | Allow | 28 | 3 | 1 | Yes | No |
| 17508066 | MUSCLE TREATMENT COMPOSITION AND METHOD OF MAKING SAME | October 2021 | April 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17502478 | METHODS FOR CULTURING FILAMENTOUS FUNGI IN FERMENTATION MEDIA | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17502486 | Methods for culturing filamentous fungi in fermentation media | October 2021 | March 2022 | Allow | 5 | 1 | 0 | No | No |
| 17502448 | Methods for culturing filamentous fungi in fermentation media | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17501325 | COMPOSITION AND METHOD FOR CELL CULTURE SUSTAINED RELEASE | October 2021 | September 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17492386 | TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS | October 2021 | July 2024 | Allow | 34 | 1 | 1 | No | No |
| 17486302 | METHOD FOR USING BIVALVE WASTE AS MEDIA FOR MICRO-ALGAL PRODUCTION | September 2021 | February 2023 | Allow | 16 | 1 | 0 | No | No |
| 17473501 | METHOD FOR CALORIMETRIC DETERMINATION OF THE LIPOPROTEIN LIPASE ACTIVITY IN HUMAN PLASMA ENVIRONMENT | September 2021 | January 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17411983 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | August 2021 | February 2022 | Allow | 6 | 1 | 0 | No | No |
| 17445827 | PROBIOTIC THERAPIES FOR DEVELOPMENTAL DISORDERS AND OTHER NEUROLOGICAL DISORDERS | August 2021 | October 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17407283 | NANO-ENZYME CONTAINERS FOR TEST ELEMENTS | August 2021 | November 2024 | Allow | 39 | 1 | 1 | No | No |
| 17431212 | MEDIUM SUPPLEMENT FOR HIGH-YIELD INDUSTRIAL CULTURE OF FASTIDIOUS ANAEROBES AND MEDIUM COMPOSITION CONTAINING THE SAME | August 2021 | May 2022 | Allow | 9 | 2 | 0 | Yes | No |
| 17396330 | MODULATION OF THE GUT MICROBIOME TO TREAT MENTAL DISORDERS OR DISEASES OF THE CENTRAL NERVOUS SYSTEM | August 2021 | April 2025 | Allow | 44 | 1 | 1 | No | No |
| 17427617 | METHOD FOR SCREENING THERAPEUTIC TARGET OF ACUTE GASTROINTESTINAL SYNDROME AND USE OF TIGAR TARGET IN PREPARATION OF MEDICINE FOR TREATING RADIATION-INDUCED GASTROINTESTINAL SYNDROME | July 2021 | August 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17425582 | PROTEOLYTIC ENZYME COMPOSITION | July 2021 | December 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17381843 | THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND/OR PREVENTION OF FOOD ALLERGY | July 2021 | June 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17382000 | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same | July 2021 | March 2026 | Abandon | 56 | 4 | 1 | No | No |
| 17378619 | BLADDER INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS | July 2021 | August 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17355749 | Animal Feeds and Feed Premixes Containing Betaine Hydrochloride and a Phytase | June 2021 | January 2024 | Allow | 30 | 1 | 0 | No | No |
| 17354306 | MICROBIAL COMPOSITIONS AND METHODS FOR RUMINANT HEALTH AND PERFORMANCE | June 2021 | August 2023 | Allow | 26 | 5 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAVIS, RUTH A.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DAVIS, RUTH A works in Art Unit 1699 and has examined 391 patent applications in our dataset. With an allowance rate of 74.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner DAVIS, RUTH A's allowance rate of 74.9% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DAVIS, RUTH A receive 2.28 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DAVIS, RUTH A is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.7% benefit to allowance rate for applications examined by DAVIS, RUTH A. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 20.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 48.7% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 33.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 32% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 70.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 62.0% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.